CEL-SCI Corporation, a clinical stage cancer immunotherapy company, announced the pricing of a $5.7 million offering of its common stock, conducted at-the-market under NYSE American rules. The offering involves 1,500,000 shares priced at $3.82 each. The anticipated gross proceeds, prior to deduction of fees and expenses, total approximately $5.7 million. The closing date for the offering is expected to be July 14, 2025, contingent on customary conditions. Proceeds from the offering will support the continued development of Multikine, as well as general corporate purposes and working capital. ThinkEquity serves as the sole placement agent for the transaction.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.